Company news

Share this article:
Azur Pharma has entered into an agreement with BioSante Pharmaceuticals to acquire US rights to Elestrin, a gel formulation of estradiol indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, for $3.3 million. FDA approved Elestrin in December 2006, and the product is patented through June 2022.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions